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Edited by Veli-Pekka LehtoAbstract Urokinase receptor (uPAR) plays a key role in phys-
iological and pathological processes sustained by an altered cell
migration. We have developed peptides carrying amino acid
substitutions along the Ser88-Arg-Ser-Arg-Tyr92 (SRSRY)
uPAR chemotactic sequence. The peptide pyro glutamic acid
(pGlu)-Arg-Glu-Arg-Tyr-NH2 (pERERY-NH2) shares the same
binding site with SRSRY and competes with N-formyl-Met-Leu-
Phe (fMLF) for binding to the G-protein-coupled N-formyl-
peptide receptor (FPR). pERERY-NH2 is a dose-dependent
inhibitor of both SRSRY- and fMLF-directed cell migration,
and prevents agonist-induced FPR internalization and fMLF-
dependent ERK1/2 phosphorylation. pERERY-NH2 is a new
and potent uPAR inhibitor which may suggest the generation
of new pharmacological treatments for pathological conditions
involving increased cell migration.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Cell migration contributes to several diseases driven by aber-
rant cell motility, such as chronic inﬂammation, vascular dis-
ease and tumor metastasis [1,2]. The receptor for the
urokinase-type plasminogen activator (uPAR) plays an impor-
tant role in physiological processes such as wound healing,
inﬂammation and stem cell mobilization, and in severe patho-
logical conditions such as tumour invasion and metastasis [3].
uPAR is a three domains (D1, D2 and D3) protein anchored to
the cell membrane with a glycosyl–phosphatidyl–inositol [4].
uPAR can form a complete signalling unit only when associ-Abbreviations: uPAR, urokinase receptor; pGlu, pyro glutamic acid;
fMLF, N-formyl-Met-Leu-Phe; FPR, N-formyl-peptide receptor
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doi:10.1016/j.febslet.2008.03.001ated with transmembrane receptors, such as G-protein-cou-
pled receptors [5–8]. The uPAR engagement with uPA
favours the exposure of the chemotactic Ser88-Arg-Ser-Arg-
Tyr92 sequence which belongs to a ﬂexible linker connecting
the uPAR domains D1 and D2 [9,10]. Residues 91–94 are con-
served across species [11]. Through Ala-scan, we have found
that both Arg residues of the peptide H-Ser-Arg-Ser-Arg-
Tyr-OH (SRSRY) are essential to any signalling activity [12].
SRSRY promotes cytoskeletal rearrangements and directional
cell migration by binding to the low (FPRL1) or the high
N-formyl-peptide receptor (FPR) aﬃnity formyl peptide recep-
tors [12–14].
We have developed a series of synthetic peptides carrying
speciﬁc amino acid substitutions along the SRSRY sequence.
In this article, we report that the peptide pyro glutamic acid
(pGlu)-Arg-Glu-Arg-Tyr-NH2 (pERERY-NH2) prevents
SRSRY chemotactic activity by antagonizing the G-protein-
coupled FPR.2. Materials and methods
2.1. Peptide synthesis and puriﬁcation
Peptides were synthesized by the solid phase approach using stan-
dard Fmoc methodology in a manual reaction vessel [15]. Peptides
were puriﬁed by a RP-HPLC C18 column (Vydac 218TP1010) to a
99% purity, as determined by analytical RP-HPLC. Molecular weights
were conﬁrmed by mass spectrometry.
2.2. Cell cultures
Human Embryonic Kidney HEK-293, Rat Basophilic Leukemia
RBL-2H3, and RBL-2H3/ETFR [16] cells were grown in DMEM sup-
plemented with 10% FBS, 100 IU/ml penicillin and 50 lg/ml strepto-
mycin.
2.3. Motility assays
Cell migration assays were performed in modiﬁed Boyden chambers
for 4 h or in Dunn chambers for 6 h as previously described [12,17].
2.4. Binding assay
Five micrograms recombinant D2(88–183) uPAR fragment (Calbio-
chem) were biotinylated using a kit purchased from Amersham accord-
ing to the manufacturers recommendations. HEK-293 cells (1 · 106)
were harvested, incubated with or without the indicated eﬀectors for
15 min at 23 C and then exposed to biotinylated D2(88–183) diluted
in binding buﬀer (DMEM containing 1 mg/ml BSA) for 2 h at 4 C.blished by Elsevier B.V. All rights reserved.
Table 1
Eﬀects of SRSRY-derived Glu-substituted peptides on SRSRY-
directed HEK-293 cell migration
Peptides (10 nM) Cell migration
None 100 ± 7
H-Glu-Arg-Ser-Arg-Tyr-OH 99 ± 5
H-Ser-Glu-Ser-Arg-Tyr-OH 101 ± 1
H-Ser-Arg-Glu-Arg-Tyr-OH 69 ± 2
H-Ser-Arg-Ser-Glu-Tyr-OH 98 ± 4
H-Ser-Arg-Ser-Arg-Glu-OH 100 ± 8
Chemotactic response of HEK-293 cells to 10 nM SRSRY in a Boyden
chamber assay in the presence or in the absence of 10 nM substituted
peptides. SRSRY-dependent cell migration (280% of the basal
migration) was considered as 100% and cell migration in the presence
of substituted peptides was calculated as a percentage of that. Data
points are the means ± S.D. of three independent experiments.
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[18], separated onto a 12.5% SDS–PAGE, and analysed for the biotin
content by Western blot.
2.5. Fluorescence microscopy
Cells, grown on glass slides to semi-conﬂuence, were incubated with
diluents, or the indicated eﬀectors, for 60 min at 4 C or 30 min at
37 C. Then, cells were washed with PBS, exposed to N-formyl-Nle-
Leu-Phe-Nle-Tyr-Lys ﬂuorescein (Molecular Probes) for additional
60 min at 4 C or 30 min at 37 C and analysed by a Zeiss LMS510
confocal microscope. Image analysis and quantization of the cell-asso-
ciated ﬂuorescence were performed on 100 cells, recorded in two diﬀer-
ent experiments, by using the Axio Vision 4.4 software (Carl Zeiss).
2.6. ERK1/2 phosphorylation assay
Cell lysates were prepared with RIPA buﬀer and cleared by centrifu-
gation as previously reported [12]. Fifty micrograms of proteins/sam-
ple were separated on a 10% SDS–PAGE, and transferred to a
nitrocellulose membrane. Western blot analysis was performed using
2 lg/ml anti-phospho-ERK1/2 polyclonal antibody. Total ERK1/2
was assessed by re-probing ﬁlters with 2 lg/ml anti-ERK1 and anti-
ERK2 monoclonal antibodies. Densitometry of autoradiographic
bands, was performed by NIH (Bethesda, MD) Image 1.62 software.
2.7. Cytosolic Ca2+ measurement
Changes in intracellular Ca2+ levels were measured observing with a
confocal Zeiss LSM510 microscope (excitation: 488 nm, emission band
pass: 500–550) single cells loaded with 5 lM ﬂuo-3AM (Invitrogen-
Molecular Probes) for 45 min at 37 C in humidiﬁed air containing
5% CO2, and continuously perfused with Krebs solution (160 mM
NaCl, 5 mM KCl, 10 mM glucose, 10 mM Hepes, 1.2 mM MgCl2,
1.5 mM CaCl2, pH 7.4), with or without the peptide under investiga-
tion. Oﬄine analysis was performed using the Image J1.37 software
(http://rsb.info.nih.gov/ij/index.html) and the Time series analyzer
plug-in (http://rsb.info.nih.gov/ij/plugins/time-series.html).
2.8. Statistical analysis
The results were analysed using the Students t-test. A value of
P < 0.001 was considered to be signiﬁcant.3. Results
3.1. Selection of pERERY-NH2 as an antagonist of the SRSRY-
directed cell migration
As a ﬁrst approach, ﬁve Glu-scanned SRSRY peptides were
synthesized and tested for their ability to promote or to pre-
vent directional cell migration in Boyden chambers. Since all
peptides failed to promote HEK-293 cell migration up to
100 nM concentration (not shown), we tested their ability to
inhibit SRSRY-dependent cell migration. As expected, HEK-
293 cells responded to SRSRY motogen stimulus (280% of
the basal migration) [12]. Interestingly, the addition to the low-
er chamber of equimolar concentrations of H-Ser-Arg-Glu-
Arg-Tyr-OH and SRSRY, caused a 31% inhibition of HEK-
293 cell migration (Table 1), while the other peptides were inef-
fective. This ﬁnding suggested that the Arg-Glu-Arg central
core may be relevant to the inhibition of the SRSRY-depen-
dent cell migration. Therefore, the SRSRY double mutants
listed in Fig. 1A were tested for their ability to inhibit
SRSRY-dependent HEK-293 cell migration. While the control
peptide H-Ala-Arg-Ala-Arg-Tyr-OH (ARARY) did not exert
any eﬀect, pGlu-Arg-Glu-Arg-Tyr-OH and H-Glu-Arg-Glu-
Arg-Tyr-OH, caused, at 100 pM concentration, a 45% and a
30% inhibition, respectively (Fig. 1A). Furthermore, the
C-terminal amidated peptide pGlu-Arg-Glu-Arg-Tyr-NH2
(pERERY-NH2) triggered a 70% inhibition at 100 pM concen-tration (Fig. 1A). Further characterization of pERERY-NH2
shows that this peptide inhibited SRSRY-directed HEK-293
cell migration in a dose-dependent manner. Inhibition starts
at 100 fM concentration, 50% of maximal eﬀect being reached
at 100 pM. Maximal inhibition was reached in the nM range
(Fig. 1B).
3.2. pERERY-NH2 antagonizes FPR signalling
It is known that D2(88–183) uPAR fragment binds to FPR or
FPRL1 through the SRSRY sequence [12–14]. To assess
whether pERERY-NH2 and SRSRY share the same binding
site, HEK-293 cells were pre-incubated with an excess unla-
beled D2(88–183), SRSRY, pERERY-NH2 or ARARY, and
then exposed to biotinylated D2(88–183). Eluted proteins were
analysed for their biotin content by Western blot. All eﬀectors,
with the exception of ARARY, prevented the binding of bio-
tinylated D2(88–183) to cell surface to a similar extent, suggest-
ing that both SRSRY and pERERY-NH2 recognize the same
cell surface receptor (Fig. 2A). A likely possibility is that pER-
ERY-NH2 recognizes FPR which is constitutively expressed
by HEK-293 cells [14]. To study the role of FPR, we took
advantage of RBL-2H3 cells which are devoid of FPR and
RBL-2H3/ETFR which stably express FPR [16]. In a migra-
tion assay toward N-formyl-Met-Leu-Phe (fMLF), we found
that pERERY-NH2 inhibits RBL-2H3/ETFR cell migration
in a dose-dependent manner (Fig. 2B). The inhibitory eﬀect
starts at 10 fM concentration, 50% of maximal eﬀect being
reached at 1 pM. Maximal inhibition is reached in the low
nM range (Fig. 2B). Unlike RBL-2H3 cells, RBL-2H3/ETFR
cells move toward SRSRY and fMLF, the extent of cell migra-
tion being reduced to the basal levels by 100 pM pERERY-
NH2 (Fig. 2C). In contrast, RBL-2H3 and RBL-2H3/ETFR
cell response to ﬁbronectin (Fn) [16] was not prevented by
pERERY-NH2 (Fig. 2C). This indicates that antagonistic ef-
fect of pERERY-NH2 is directed to SRSRY signalling and it
is mediated by FPR. To gain some insights into the cellular ef-
fects of pERERY-NH2, RBL-2H3/ETFR cells were grown
adherent onto a glass slide, exposed to a 10 nM fMLF gradient
containing 100 pM pERERY-NH2 or diluents in a DUNN
chamber for 6 h, and then stained with rhodamine–phalloidin.
Cells subjected to the fMLF gradient exhibited an elongated
morphology and recognisable aligned protrusions associated
to locomotion in the 80% cell population. Vice versa, the addi-
tion of pERERY-NH2 to the fMLF gradient reduced cell elon-
Fig. 1. Screening of peptide inhibitors of the SRSRY-directed cell migration. HEK-293 cells were allowed to migrate in Boyden chambers toward
10 nM SRSRY in combination with 100 fM (h), 100 pM ( ), or 100 nM (j) or increasing concentration of the indicated peptides. The extent of cell
migration in the presence of the peptides was expressed as a percentage of the SRSRY-dependent directional cell migration assessed in the absence of
peptides, considered as 100%. Data represent the means ± S.D. of three (A, *P < 0.0001 compared to SRSRY-dependent directional cell migration)
or four (B) independent experiments performed in duplicate.
Fig. 2. FPR-dependence of pERERY-NH2 inhibitory eﬀect. (A) HEK-293 cells were incubated with 500 nM D2(88–183), 500 nM SRSRY, 500 nM
pERERY-NH2, 500 nM ARARY, or diluents and subsequently exposed to 100 nM biotinylated D2(88–183). Cell surface-associated proteins were
eluted and subjected to Western blot analysis. Five microlitres of biotinylated D2(88–183) was loaded as a control. (B) Dose-dependent eﬀect of
pERERY-NH2 and ARARY on RBL-2H3/ETFR cell migration directed to 10 nM fMLF. The extent of cell migration was expressed as a percentage
of the fMLF-dependent directional cell migration in the absence of peptides (100%). The data represent the means ± S.D. of three independent
experiments performed in duplicate. (C) Chemotactic response of RBL-2H3 (h, ), or RBL-2H3/ETFR ( ,j) cells to 10 nM SRSRY, 10 nM fMLF
or 50 lg/ml ﬁbronectin (Fn), in the presence ( , ) or in the absence (h,j) of 100 pM pERERY-NH2. The extent of cell migration was expressed as
a percentage of the random cell migration assessed in the absence of chemoattractant, considered as 100% (none). The data represent the
means ± S.D. of independent experiments performed in duplicate (*P < 0.0001). (D) Representative images of rhodamine–phalloidin stained RBL-
2H3/ETFR cells subjected in a DUNN chamber to a 10 nM fMLF chemotactic gradient, in the absence or in the presence of 100 pM pERERY-NH2.
Original magniﬁcation: 100·.
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tribution along the plasma membranes in at least 75% of cell
population (Fig. 2D). Taken together, these data indicate that
FPR-mediated pERERY-NH2 inhibitory eﬀect involves amarked inhibition of cytoskeletal re-organization occurring
during locomotion.
In response to agonist-stimulation, many GPCRs, including
FPR, are internalized [19,20]. We ﬁrst evaluated the direct
1144 K. Bifulco et al. / FEBS Letters 582 (2008) 1141–1146binding of pERERY-NH2 to RBL-2H3/ETFR cells. Cells were
pre-incubated at 4 C with 100 nM fMLF, 100 nM ARARY or
increasing concentrations of pERERY-NH2 and then exposed
to N-formyl-Nle-Leu-Phe-Nle-Tyr-Lys-ﬂuorescein. As ex-
pected, RBL-2H3 cells did not bind to the ﬂuorescent fMLF
analog (not shown). However, pERERY-NH2 speciﬁcally
inhibited binding of ﬂuorescent agonist to RBL-2H3/ETFR
cells in a dose-dependent manner and to a similar extent than
fMLF (Fig. 3A). Quantization of the cell-associated ﬂuores-
cence revealed that, whereas 100 fM pERERY-NH2 was inef-
fective, pERERY-NH2 at 100 pM, 10 nM or 10 lM
concentrations caused a 72%, 98% and 94% reduction of li-
gand binding, respectively. Then, to evaluate the eﬀect of pER-
ERY-NH2 on agonist-dependent FPR internalization,
experiments were performed at 37 C. Upon exposure to ﬂuo-
rescent agonist, FPR appeared mainly internalized as indicated
by punctuate green ﬂuorescent intra-cytoplasmic spots
(Fig. 3B) which are undetectable in FPR lacking RBL-2H3Fig. 3. pERERY-NH2 inhibits FPR Signaling. Representative confocal ima
diluents (none), 100 nM fMLF, 100 pM ARARY or pERERY-NH2 at the
10 nM N-formyl-Nle-Leu-Phe-Nle-Tyr-Lys ﬂuorescein. Original magniﬁcatio
ETFR cells exposed to 10 nM fMLF or 100 pM pERERY-NH2 or diluents,
indicated times. The histogram shows the OD ratio for P-ERK1/2/ERK1/2 ba
is shown. (D) Eﬀect of 100 pM pERERY-NH2 or vehicle on 10 nM fMLF-in
traces, the time course of intracellular Ca2+ levels, measured as ﬂuo-3 ﬂuores
the presence of pERERY-NH2 or vehicle. The traces are representative of 180
106 cells which after being exposed to Krebs solution during the ﬁrst minute o
kept in the presence of this peptide throughout the entire fMLF stimulationcells (not shown). As expected, intra-cytoplasmic spots were
prevented by cell pre-incubation with 100 nM fMLF
(Fig. 3B). Unlike ARARY that was ineﬀective, cell pre-expo-
sure to 100 pM pERERY-NH2 for 30 min strongly reduced
internalization in all cell population (Fig. 3B), suggesting a
mechanism in which pERERY-NH2 inhibits cell migration
by preventing the agonist-mediated FPR internalization.
Stimulation of RBL-2H3/ETFR cells with fMLF induces
activation of several protein kinases, including MAP kinases
[21]. As expected, RBL-2H3/ETFR cell exposure to 10 nM
fMLF for 5 or 10 min triggered a time-dependent increase
of ERK1/2 phosphorylation. Vice versa, cell exposure to
100 pM pERERY-NH2 for 5 or 10 min, did not aﬀect the
basal ERK1/2 phosphorylation, but consistently decreased
the amount of fMLF-induced phosphorylated ERK1/2
(Fig. 3C).
Finally, we assessed whether pERERY-NH2 interferes with
the ability of fMLF to evoke an increase in intracellularges of RBL-2H3/ETFR cells incubated at 4 C (A) or 37 C (B) with
indicated concentrations and then exposed at 4 C (A) or 37 C (B) to
n: 630·. (C) Active (P-ERK1/2) and total ERK1/2 levels in RBL-2H3/
or a combination of 100 pM pERERY-NH2 and 10 nM fMLF for the
nds as quantiﬁed by densitometry. A representative experiment of three
duced intracellular Ca2+ response. The panel reports, as superimposed
cence intensity, in two diﬀerent cells, before and after 10 nM fMLF, in
cells perfused with vehicle before, during and after the fMLF pulse and
f recording, were switched to a pERERY-NH2-containing solution and
and during its washout.
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creased intracellular Ca2+ with a rapid peak (mean percentage
increase over baseline 577.3 ± 8.2%, n = 180 in three diﬀerent
experiments) followed by a plateau maintained until the pep-
tide was washed out (Fig. 3D). pERERY-NH2 neither modi-
ﬁed baseline intracellular Ca2+ (ﬂuo3 ﬂuorescence intensity
24.3 ± 1.0 vs. 23.9 ± 1.0, ns) nor the intracellular Ca2+ re-
sponse evoked by further addition of fMLF (mean percentage
increase over baseline 595.2 ± 15.7%; n = 106 in three diﬀerent
experiments) (Fig. 3D). Overall, our ﬁndings indicate that
pERERY-NH2 inhibits SRSRY function by antagonizing
FPR-dependent MAP-K activation without interfering with
the eﬀects of this receptor on intracellular Ca2+ homeostasis.4. Discussion
We have developed synthetic peptides carrying speciﬁc ami-
no acid substitutions along the SRSRY uPAR sequence.
Among these, the peptide H-Ser-Arg-Glu-Arg-Tyr-OH was se-
lected for its ability to inhibit SRSRY-directed cell migration.
Further modiﬁcations led to the generation of the peptide
pGlu-Arg-Glu-Arg-Tyr-NH2 (pERERY-NH2), which is a po-
tent inhibitor of both SRSRY- and fMLF-directed cell migra-
tion. In an eﬀort to characterize the molecular mechanisms
underlying the activity of pERERY-NH2, we demonstrated
that pERERY-NH2 shares the same binding site with SRSRY
on the FPR and prevents: (a) binding of a ﬂuorescent fMLF
analogue to RBL-2H3/ETFR cell surfaces; (b) fMLF-directed
cell migration of RBL-2H3/ETFR cells stably expressing FPR;
(c) agonist-dependent FPR internalization and ERK1/2 phos-
phorylation. These remarkable eﬀects are due to its binding to
the FPR.
Many reports clearly show the involvement of the uPAR in
cell migration, thus suggesting that this receptor may be re-
garded as a new molecular target for therapy of diseases sus-
tained by increased cell motility. In this respect, eﬀorts have
been made to interfere with the uPA/uPAR or integrin/uPAR
interactions [9,21,22]. To the best of our knowledge, pER-
ERY-NH2 is the ﬁrst uPAR inhibitor that speciﬁcally impairs
the uPAR/FPR interaction.
Furthermore, pERERY-NH2 can be regarded also as a true
FPR antagonist. A large body of literature shows that FPRs
govern a variety of cellular functions, including chemotaxis
which requires ERK1/2 phosphorylation, but not a cytosolic
Ca2+ increase [23]. In our experiments, pERERY-NH2 blocks
FPR-mediated chemotaxis and ERK1/2 phosphorylation,
without aﬀecting intracellular calcium mobilization. Since we
have not detected any cell response following exposure to
pERERY-NH2 alone, it is possible that this peptide might be-
have as a neutral antagonist. pERERY-NH2 appeared to rec-
ognize FPR with a higher aﬃnity (pM) than fMLF or SRSRY
(nM) which instead promote chemotaxis. In this respect, pER-
ERY-NH2 could act as an inverse agonist by shifting, upon
binding to FPR, the active state of the receptor toward the
inactive one. Regarding the speciﬁc aﬃnity of pERERY-
NH2 for its target, competition experiments with a ﬂuorescent
fMLF analogue showed that a concentration as low as 100 pM
pERERY-NH2 prevents both internalization and ligand-up-
take of FPR. Labelled pERERY-NH2 is unavailable to us,
and therefore we could not determine the aﬃnity of pER-
ERY-NH2 for the FPR. How pERERY-NH2 interacts withFPR and what structural basis dictates its high aﬃnity for
FPR remain to be investigate. Also, it would be interesting
to determine whether pERERY-NH2 behaves as a neutral
antagonist or an inverse agonist for FPR. This issue is relevant
in vivo for potential therapeutic applications, since inverse
agonist eﬀects are associated with receptor activation and inac-
tivation, whereas neutral antagonism produces no eﬀect when
administered alone, but blocks the eﬀects of agonists and in-
verse agonists [19].
pERERY-NH2 is a novel FPR antagonist exhibiting a high-
er aﬃnity as compared with other antagonists of FPR that
have been investigated for their putative role as therapeutic
agents [24,25]. In particular, the cyclic undecapeptide, cyclo-
sporine H is a potent and selective FPR inverse agonist which
prevents both FPR-mediated Ca2+ mobilization and chemo-
taxis [24]. pERERY-NH2 behaves diﬀerently from cyclospor-
ine H because it does not prevent FPR-mediated Ca2+
mobilization and it is much more potent than cyclosporine H
in inhibiting fMLF-induced chemotaxis (IC50 = 1 pM and
49 nM, respectively).
GPCRs have a crucial role in the physiopathology of im-
mune system as well as in cancer progression and metastasis.
In particular, accumulating evidence suggests that modulating
GPCR function might delay the progression of many cancers
and their spread to distant organs [26]. Given the ﬁnding that
pERERY-NH2 inhibits cell migration by antagonizing FPR, it
is reasonable to foresee that this peptide may be employed to
develop new drugs for the treatment of diseases that are sus-
tained by a chronic excess of cell migration, such as inﬂamma-
tory diseases, tumor spread and metastases.
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